Your browser doesn't support javascript.
loading
Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants.
Stopfer, Lauren E; Gajadhar, Aaron S; Patel, Bhavin; Gallien, Sebastien; Frederick, Dennie T; Boland, Genevieve M; Sullivan, Ryan J; White, Forest M.
Afiliação
  • Stopfer LE; Department of Biological Engineering, Koch Institute for Integrative Cancer Research, Center for Precision Cancer Medicine, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Gajadhar AS; Thermo Fisher Scientific, San Jose, CA 95134.
  • Patel B; Thermo Fisher Scientific, Rockford, IL 61101.
  • Gallien S; Thermo Fisher Scientific, Precision Medicine Science Center, Cambridge, MA 02139.
  • Frederick DT; Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Boland GM; Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Sullivan RJ; Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • White FM; Department of Biological Engineering, Koch Institute for Integrative Cancer Research, Center for Precision Cancer Medicine, Massachusetts Institute of Technology, Cambridge, MA 02139; fwhite@mit.edu.
Proc Natl Acad Sci U S A ; 118(37)2021 09 14.
Article em En | MEDLINE | ID: mdl-34497125
ABSTRACT
Absolute quantification measurements (copies per cell) of peptide major histocompatibility complex (pMHC) antigens are necessary to inform targeted immunotherapy drug design; however, existing methods for absolute quantification have critical limitations. Here, we present a platform termed SureQuant-IsoMHC, utilizing a series of pMHC isotopologues and internal standard-triggered targeted mass spectrometry to generate an embedded multipoint calibration curve to determine endogenous pMHC concentrations for a panel of 18 tumor antigens. We apply SureQuant-IsoMHC to measure changes in expression of our target panel in a melanoma cell line treated with a MEK inhibitor and translate this approach to estimate antigen concentrations in melanoma tumor biopsies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Benzimidazóis / Antígenos de Histocompatibilidade Classe I / Apresentação de Antígeno / MAP Quinase Quinase 1 / Melanoma / Antígenos de Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Benzimidazóis / Antígenos de Histocompatibilidade Classe I / Apresentação de Antígeno / MAP Quinase Quinase 1 / Melanoma / Antígenos de Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article